Drug Profile
Oleclumab - AstraZeneca
Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI-9447Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; European Network of Gynaecological Oncological Trial Groups; Jules Bordet Institute; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
- Phase I/II Colorectal cancer
- No development reported Bladder cancer; Solid tumours
Most Recent Events
- 04 Oct 2023 University Health Network plans a phase II trial for Pancreatic Cancer (IV) in October 2023 (NCT06060405)
- 18 Jul 2023 MedImmune completes the phase II COAST trial for Non-small cell lung cancer (Combination therapy, Monotherapy, Second line therapy or greater, Late stage disease, Unresectable/Inoperable) in US, Canada, France, Hong Kong, Italy, Poland, Portugal, Spain and Taiwan (IV) (NCT03822351)
- 02 Jun 2023 Updated adverse events and efficacy data from a phase I/II trial in Pancreatic cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)